Inpatient management of hospitalized patients with type 2 diabetes

Current Diabetes Reports

Volumn 4, Issue 5, 2004, Pages 346-351

  Ahmann, Andrew J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH SERVICE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INTENSIVE CARE UNIT; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT CARE; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 8344253626     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-004-0036-2     Document Type: Review

References (39)

1. Clement S, Braithwaite SS, Magee MF, et al.: Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004, 27:553-597.
2. Garber AJ, Moghissi ES, Bransome ED Jr, et al.: American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 2004, 10: 7-82.
3. Department of Health and Human Services, Centers for Disease Control and Prevention: National Diabetes Fact Sheet. 2003. http://www.cdc.gov/diabetes/pubs/factsheet.htm. Accessed July 2004.
4. National Center for Chronic Disease Prevention and Health Promotion: Data & Trends: Diabetes Surveillance System. http://www.cdc.gov/diabetes/statistics/index.htm. Accessed July 2004.
5. Franklin K, Goldberg RJ, Spencer F, et al.: Implications of diabetes in patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med 2004, 164:1457-1463.
6. Gray CS, Scott JF, French JM, et al.: Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing 2004, 33: 1-77.
7. Umpierrez GE, Isaacs SD, Bazargan N, et al.: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002, 87: 78-982.
8. Le Roith D: Molecular mechanisms by which metabolic control may improve outcomes. Endocr Pract 2004, 10(suppl 2): 7-62.
9. Marik PE, Raghavan M: Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004, 30: 48-756.
10. Andersen SK, Gjedsted J, Christiansen C, Tonnesen E: The roles of insulin and hyperglycemia in sepsis pathogenesis. J Leukoc Biol 2004, 75:413-421.
11. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997, 314:1512-1515.
12. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999, 67:352-360; discussion 360-362.
13. Van den Berghe GP, Wouters P, Weekers F, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367.
14. Furnary AP, Gao G, Grunkemeier GL, et al.: Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003, 125:1007-1021.
15. Furnary AP, Wu Y, Bookin SO: Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. Endocr Pract 2004, 10(suppl 2):21-33.
16. Estrada CA, Young JA, Nifong LW, Chitwood WR Jr: Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg 2003, 75:1392-1399.
17. Lazar HL, Chipkin SR, Fitzgerald CA, et al.: Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004, 109:1497-1502.
18. Christiansen C, Toft P, Jorgensen HS, et al.: Hyperglycaemia and mortality in critically ill patients: a prospective study. Intensive Care Med 2004, 30:1685-1688.
19. Finney SJ, Zekveld C, Elia A, Evans TW: Glucose control and mortality in critically ill patients. JAMA 2003, 290: 041-2047.
20. Laird AM, Miller PR, Kilgo PD, et al.: Relationship of early hyperglycemia to mortality in trauma patients. J Trauma 2004, 56:1058-1062.
21. McMullin J, Brozek J, Jaeschke R, et al.: Glycemic control in the ICU: a multicenter survey. Intensive Care Med 2004, 30:798-803.
22. Coursin DB, Connery LE, Ketzler JT: Perioperative diabetic and hyperglycemic management issues. Crit Care Med 2004, 32(4 suppl):S116-S125.
23. Van den Berghe GH: Role of intravenous insulin therapy in critically ill patients. Endocr Pract 2004, 10(suppl 2 : 7-20.
24. Gray CS, Hildreth AJ, Alberti GK, et al.: Poststroke hyperglycemia: natural history and immediate management. Stroke 2004, 35:122-126.
25. Goldberg PA, Siegel MD, Sherwin RS, et al.: Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004, 27: 61-467.
26. Kanji S, Singh A, Tierney M, et al.: Standardization of intravenous insulin therapy improves the efficiency and safety of blood glucose control in critically ill adults. Intensive Care Med 2004, 30:804-810.
27. Trence DL, Kelly JL, Hirsch IB: The rationale and management of hyperglycemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab 2003, 88: 430-2437.
28. Markovitz LJ, Wiechmann RJ, Harris N, et al.: Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery. Endocr Pract 2002, 8: 0-18.
29. Bode BW, Braithwaite SS, Steed RD, Davidson PC: Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy. Endocr Pract 2004, 10(suppl 2):71-80.
30. Van den Berghe G, Wouters PJ, Bouillon R, et al.: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003, 31: 59-366.
31. Dandona P, Aljada A, Bandyopadhyay A: The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care 2003, 26:516-519.
32. Hirsch IB: Effect of insulin therapy on nonglycemic variables during acute illness. Endocr Pract 2004, 10(suppl 2):63-70.
33. Calabrese AT, Coley KC, DaPos SV, et al.: Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002, 162:434-437.
34. Emslie-Smith AM, Boyle DI, Evans JM, et al.: Contraindications to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001, 18:483-488.
35. Masoudi FA, Wang Y, Inzucchi SE, et al.: Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003, 290:81-85.
36. Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003, 108: 941-2948.
37. Mudaliar S, Chang AR, Henry RR: Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003, 9:406-416.
38. Magee MF, Clement S: Subcutaneous insulin therapy in the hospital setting: issues, concerns, and implementation. Endocr Pract 2004, 10(suppl 2):81-88.
39. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003, 289:2254-2264.